ClinicalTrials.gg
CompletedNCT01914757Updated Jan 25, 2017Results posted

Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist

A Phase 3 interventional study of Benralizumab and Placebo in Asthma, sponsored by AstraZeneca. Completed at 217 sites in 11 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-01-25.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,508
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.

Enrollment
2nd of 39
2,508 · median 128
Started
2013
with 2 others
Phase 3
20 of 39
1 open now
Registered
7th of 39
by date
Lead sponsor
24 of 39
AstraZeneca

Among the 39 studies testing benralizumab in Asthma, this one is the 2nd largest by enrollment, is one of 3 that started in 2013, is one of 20 in phase 3, and was the 7th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About benralizumab

benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing benralizumab in Asthma, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether Benralizumab reduces the exacerbation rate in patients with a history of asthma exacerbations and uncontrolled asthma receiving ICS-LABA with or without oral corticosteroids and additional asthma controllers.

03

Conditions studied

  • Asthma

Keywords

  • Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases
04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of prior to any study specific procedures
  2. Female and male aged 12 to 75 years, inclusively, at the time of Visit 1
  3. History of physician-diagnosed asthma requiring treatment with medium-to-high dose ICS (>250µg fluticasone dry powder formulation equivalents total daily dose) and a LABA, for at least 12 months prior to Visit 1.
  4. Documented treatment with ICS and LABA for at least 3 months prior to Visit 1 with or without oral and additional asthma controllers. The ICS and LABA can be parts of a combination product or given by separate inhalers. The ICS dose must be greater than or equal to 500 μg/day fluticasone propionate dry powder formulation or equivalent daily. For ICS/LABA combination preparations, the mid-strength approved maintenance dose in the local country will meet this ICS criterion.

Exclusion criteria

Exclusion criteria:

  1. pulmonary disease other than asthma (e.g. active lung infection, , bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (e.g. allergic bronchopulmonary aspergillosis/mycosis, Churg- Strauss syndrome, hypereosinophilic syndrome)
  2. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:

    • Affect the safety of the patient throughout the study
    • Influence the findings of the studies or their interpretations
    • Impede the patient's ability to complete the entire duration of study
  3. Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date is obtained or during the screening/run-in period
  4. Any clinically significant abnormal findings in physical examination, vital signs, haematology, clinical chemistry, or urinalysis during screening/run-in period, which in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
2,508 participants (actual)

Study arms

  • Experimental
    Benralizumab 30 mg q.4 weeks

    Benralizumab administered subcutaneously every 4 weeks

    Biological: Benralizumab

  • Experimental
    Benralizumab 30 mg q.8 weeks

    Benralizumab administered subcutaneously every 8 weeks

    Biological: Benralizumab

  • Placebo comparator
    Placebo

    Placebo administered subcutaneously

    Biological: Placebo

Interventions

  • BiologicalBenralizumab

    Benralizumab subcutaneously on study week 0 until study week 52 inclusive.

  • BiologicalPlacebo

    Placebo subcutaneously on study week 0 until study week 52 inclusive.

06

What researchers measure

Primary outcomes

  1. Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils >=300/uL

    The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF.

    Time frame: Immediately following the first administration of study drug through Study Week 56.

Secondary outcomes

  1. Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils <300/uL

    The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF.

    Time frame: Immediately following the first administration of study drug through Study Week 56.

  2. Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils >=300/uL

    Time frame: Immediately following the first administration of study drug through Study Week 56.

  3. Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils <300/uL

    Time frame: Immediately following the first administration of study drug through Study Week 56.

  4. Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils >=300/uL

    Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma). Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.

    Time frame: Immediately following the first administration of study drug through Study Week 56.

  5. Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils <300/uL

    Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma). Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.

    Time frame: Immediately following the first administration of study drug through Study Week 56.

  6. Change in Asthma Rescue Medication Use

    Change from Baseline to Week 56 in number of Rescue medication use (puffs/day)

    Time frame: Immediately following the first administration of study drug through Study Week 56.

  7. Home Lung Function Assessments Based on PEF

    Change from Baseline to Week 56 in Home lung function (morning and evening Peak expiratory flow \[PEF\])

    Time frame: Immediately following the first administration of study drug through Study Week 56.

  8. Proportion of Nights With Awakening Due to Asthma

    Change from Baseline to Week 56 on Proportion of Nights with awakening due to asthma

    Time frame: Immediately following the first administration of study drug through Study Week 56.

  9. Mean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils >=300/uL

    ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \<=0.75 indicates well-controlled asthma, scores between 0.75 to \<=1.5 indicate partly controlled asthma, and \>1.5 indicates not well controlled asthma.

    Time frame: Immediately following the first administration of study drug through Study Week 56.

  10. Mean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils <300/uL

    ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \<=0.75 indicates well-controlled asthma, scores between 0.75 to \<=1.5 indicate partly controlled asthma, and \>1.5 indicates not well controlled asthma.

    Time frame: Immediately following the first administration of study drug through Study Week 56.

  11. Number of Patients With >=1 Asthma Exacerbation

    Time frame: Immediately following the first administration of study drug through Study Week 56

  12. Time to First Asthma Exacerbation

    Time frame: Immediately following the first administration of study drug through Study Week 56

  13. Annual Rate of Asthma Exacerbation Resulting Emergency Room Visits and Hospitalizations

    Annual rate of asthma exacerbations that are associated with an emergency room visit or a hospitalization (adjudicated)

    Time frame: Immediately following the first administration of study drug through Study Week 56.

  14. Pharmacokinetics of Benralizumab

    Mean PK Concentration at each visit

    Time frame: Baseline, Week 4, Week 8, Week 16, Week 24, Week 32, Week 40, Week 48, Week 56, Week 60

  15. Immunogenicity of Benralizumab

    Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at \>=2 post-baseline assessments (with \>=16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive is defined as having at least one post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.

    Time frame: Pre-treatment until end of follow-up

  16. Extent of Exposure

    Extent of exposure is defined as the duration of treatment in days

    Time frame: Immediately following the first administration of study drug through Study Week 56

  17. Mean Change From Baseline to Week 56 in AQLQ(S)+12

    AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of \>=0.5 are considered clinically meaningful.

    Time frame: Immediately following the first administration of study drug through Study Week 56

  18. Change From Baseline to Week 56 in EQ-5D-5L VAS

    EQ-5D-5L VAS is to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.

    Time frame: Immediately following the first administration of study drug through Study Week 56

  19. Mean Work Productivity Loss Due to Asthma

    WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Work productivity loss is derived by sum of percentage of missed work due to asthma and product of percentage of actual working hours times degree of asthma affecting work productivity while working. Percentage of missed work due to asthma is calculated by number of hours missed work due to asthma divided by total number of hours missed work plus number of hours actually worked. This is only applicable to patients who were employed.

    Time frame: Immediately following the first administration of study drug through Study Week 56

  20. Mean Productivity Loss Due to Asthma in Classroom

    WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Classroom productivity loss is derived by sum of percentage of missed classes due to asthma and product of percentage of actual hours attending classes times degree of asthma affecting classroom productivity. Percentage of missed classes due to asthma is calculated by number of hours missed classes due to asthma divided by total number of hours missed classes plus number of hours actually attending classes. This is only applicable for patients who took classes.

    Time frame: Immediately following the first administration of study drug through Study Week 56

  21. Number of Participants That Utilized Health Care Resources

    Time frame: Immediately following the first administration of study drug through Study Week 56

  22. Patient and Clinician Assessment of Response to Treatment

    CGIC (clinician global impression of change), and PGIC (patient global impression of change) are overall evaluation of response to treatment, conducted separately by investigator and patient using a 7-point rating scale, ranging from 1 (Very much Improved), to 7 (Very much Worse). This endpoint was added after the second protocol amendment, thus not all patients had data to be analyzed.

    Time frame: Immediately following the first administration of study drug through Study Week 56

07

Results

Posted Jan 25, 2017

Participant flow

Participant flow — Overall Study
MilestoneBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Started425441440
Completed389390402
Not completed365138
Withdrew: Severe non-compliance to protocol312
Withdrew: Lost to follow-up586
Withdrew: Withdrawal by subject152719
Withdrew: Death221
Withdrew: Adverse event434
Withdrew: Study specific withdrawal criteria010
Withdrew: Eligibility criteria not fulfilled202
Withdrew: Other reasons594

Outcome measures

PrimaryAnnual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils >=300/uL

The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF.

Time frame:
Immediately following the first administration of study drug through Study Week 56.
Reported as:
Least squares mean · Events/year
Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils >=300/uL
Events/yearBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils >=300/uL0.6 (0.48 to 0.74)0.66 (0.54 to 0.82)0.93 (0.77 to 1.12)
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Negative Binomial · p = 0.002 · Rate ratio: 0.64 · 95% CI 0.49 to 0.85Model includes covariates treatment group, region, number of exacerbations in the previous year, and use of maintenance oral corticosteroids
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Negative Binomial · p = 0.019 · Rate ratio: 0.72 · 95% CI 0.54 to 0.95Model includes covariates treatment group, region, number of exacerbations in the previous year, and use of maintenance oral corticosteroids.
SecondaryAnnual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils <300/uL

The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF.

Time frame:
Immediately following the first administration of study drug through Study Week 56.
Reported as:
Least squares mean · Events/year
Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils <300/uL
Events/yearBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils <300/uL0.78 (0.59 to 1.02)0.73 (0.55 to 0.95)1.21 (0.96 to 1.52)
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Negative Binomial · p = 0.015 · Rate ratio: 0.64 · 95% CI 0.45 to 0.92Model includes covariates treatment group, region, number of exacerbations in the previous year, and use of maintenance oral corticosteroids
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Negative Binomial · p = 0.005 · Rate ratio: 0.6 · 95% CI 0.42 to 0.86Model includes covariates treatment group, region, number of exacerbations in the previous year, and use of maintenance oral corticosteroids.
SecondaryMean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils >=300/uL
Time frame:
Immediately following the first administration of study drug through Study Week 56.
Reported as:
Mean · Liter
Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils >=300/uL
LiterBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils >=300/uL0.34 ± 0.4690.332 ± 0.5180.206 ± 0.471
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.005 · Mean difference (final values): 0.125 · 95% CI 0.037 to 0.213Model includes treatment, baseline pre-BD FEV1, region, use of OCS, visit, and treatment by visit
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.01 · Mean difference (final values): 0.116 · 95% CI 0.028 to 0.204Model includes treatment, baseline pre-BD FEV1, region, use of OCS, visit, and treatment by visit
SecondaryMean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils <300/uL
Time frame:
Immediately following the first administration of study drug through Study Week 56.
Reported as:
Mean · Liter
Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils <300/uL
LiterBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils <300/uL0.221 ± 0.4410.164 ± 0.3580.135 ± 0.437
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.268 · Mean difference (final values): 0.064 · 95% CI -0.049 to 0.176Model includes treatment, baseline pre-BD FEV1, region, use of OCS, visit, and treatment by visit
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.786 · Mean difference (final values): -0.015 · 95% CI -0.127 to 0.096Model includes treatment, baseline pre-BD FEV1, region, use of OCS, visit, and treatment by visit
SecondaryMean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils >=300/uL

Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma). Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.

Time frame:
Immediately following the first administration of study drug through Study Week 56.
Reported as:
Mean · Scores on a scale
Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils >=300/uL
Scores on a scaleBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils >=300/uL-1.33 ± 1.23-1.4 ± 1.17-1.2 ± 1.19
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.224 · Mean difference (final values): -0.12 · 95% CI -0.32 to 0.07Model includes treatment, baseline Asthma symptom score, region, use of OCS, visit, and visit by treatment.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.019 · Mean difference (final values): -0.23 · 95% CI -0.43 to -0.04Model includes treatment, baseline Asthma symptom score, region, use of OCS, visit, and visit by treatment.
SecondaryMean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils <300/uL

Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma). Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.

Time frame:
Immediately following the first administration of study drug through Study Week 56.
Reported as:
Mean · Scores on a scale
Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils <300/uL
Scores on a scaleBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils <300/uL-1.05 ± 1.14-0.95 ± 1.13-0.88 ± 1.12
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.287 · Mean difference (final values): -0.16 · 95% CI -0.44 to 0.13Model includes treatment, baseline Asthma symptom score, region, use of OCS, visit, and visit by treatment.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.966 · Mean difference (final values): 0.01 · 95% CI -0.28 to 0.29Model includes treatment, baseline Asthma symptom score, region, use of OCS, visit, and visit by treatment.
SecondaryChange in Asthma Rescue Medication Use

Change from Baseline to Week 56 in number of Rescue medication use (puffs/day)

Time frame:
Immediately following the first administration of study drug through Study Week 56.
Reported as:
Mean · Puffs per day
Change in Asthma Rescue Medication Use
Puffs per dayBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Change in Asthma Rescue Medication Use-2.0 ± 3.64-2.92 ± 3.60-2.65 ± 9.57
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.603 · Mean difference (final values): 0.21 · 95% CI -0.58 to 0.99Model includes treatment, baseline Asthma rescue medication use, region, use of OCS, visit, and visit by treatment.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.209 · Mean difference (final values): -0.5 · 95% CI -1.29 to 0.28Model includes treatment, baseline Asthma medication use, region, use of OCS, visit, and visit by treatment.
SecondaryHome Lung Function Assessments Based on PEF

Change from Baseline to Week 56 in Home lung function (morning and evening Peak expiratory flow \[PEF\])

Time frame:
Immediately following the first administration of study drug through Study Week 56.
Reported as:
Mean · L/min
Home Lung Function Assessments Based on PEF
L/minBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Change at Week 56, Morning (n=194, 193, 197)41.745 ± 78.53443.375 ± 91.86523.961 ± 71.509
Change at Week 56, Evening (n=194, 192, 197)35.142 ± 75.48939.270 ± 89.77215.448 ± 78.341
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.029 · Mean difference (final values): 15.86 · 95% CI 1.59 to 30.12Model includes treatment, baseline morning PEF, region, use of OCS, visit, and visit by treatment.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.037 · Mean difference (final values): 15.27 · 95% CI 0.9 to 29.64Model includes treatment, baseline morning PEF, region, use of OCS, visit, and visit by treatment.
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.018 · Mean difference (final values): 17.54 · 95% CI 3.07 to 32Model includes treatment, baseline evening PEF, region, use of OCS, visit, and visit by treatment.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.004 · Mean difference (final values): 21.22 · 95% CI 6.65 to 35.79Model includes treatment, baseline evening PEF, region, use of OCS, visit, and visit by treatment.
SecondaryProportion of Nights With Awakening Due to Asthma

Change from Baseline to Week 56 on Proportion of Nights with awakening due to asthma

Time frame:
Immediately following the first administration of study drug through Study Week 56.
Reported as:
Mean · Proportion of nights
Proportion of Nights With Awakening Due to Asthma
Proportion of nightsBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Proportion of Nights With Awakening Due to Asthma-0.373 ± 0.388-0.431 ± 0.4-0.372 ± 0.405
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.4 · Mean difference (final values): -0.02 · 95% CI -0.06 to 0.03Model includes treatment, baseline prop of nights with nocturnal wakening, region, use of OCS, visit, and visit by treatment.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.146 · Mean difference (final values): -0.03 · 95% CI -0.08 to 0.01Model includes treatment, baseline prop of nights with nocturnal wakening, region, use of OCS, visit, and visit by treatment.
SecondaryMean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils >=300/uL

ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \<=0.75 indicates well-controlled asthma, scores between 0.75 to \<=1.5 indicate partly controlled asthma, and \>1.5 indicates not well controlled asthma.

Time frame:
Immediately following the first administration of study drug through Study Week 56.
Reported as:
Mean · Scores on a scale
Mean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils >=300/uL
Scores on a scaleBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Mean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils >=300/uL-1.34 ± 1.13-1.49 ± 1.13-1.21 ± 1.12
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.043 · Mean difference (final values): -0.19 · 95% CI -0.38 to -0.01Model includes treatment, baseline ACQ-6 score, region, use of OCS, visit, and visit by treatment.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.008 · Mean difference (final values): -0.25 · 95% CI -0.44 to -0.07Model includes treatment, baseline ACQ-6 score, region, use of OCS, visit, and visit by treatment.
SecondaryMean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils <300/uL

ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \<=0.75 indicates well-controlled asthma, scores between 0.75 to \<=1.5 indicate partly controlled asthma, and \>1.5 indicates not well controlled asthma.

Time frame:
Immediately following the first administration of study drug through Study Week 56.
Reported as:
Mean · Scores on a scale
Mean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils <300/uL
Scores on a scaleBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Mean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils <300/uL-1.22 ± 1.16-1.06 ± 1.02-0.83 ± 1.07
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.078 · Mean difference (final values): -0.24 · 95% CI -0.51 to 0.03Model includes treatment, baseline ACQ-6 score, region, use of OCS, visit, and visit by treatment.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.449 · Mean difference (final values): -0.1 · 95% CI -0.37 to 0.16Model includes treatment, baseline ACQ-6 score, region, use of OCS, visit, and visit by treatment.
SecondaryNumber of Patients With >=1 Asthma Exacerbation
Time frame:
Immediately following the first administration of study drug through Study Week 56
Reported as:
Number · Participants
Number of Patients With >=1 Asthma Exacerbation
ParticipantsBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Number of Patients With >=1 Asthma Exacerbation8495126
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Odds ratio (or): 0.46 · 95% CI 0.31 to 0.69Controlling for region, number of exacerbations in the previous year, use of OCS
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Cochran-Mantel-Haenszel · p = 0.023 · Odds ratio (or): 0.65 · 95% CI 0.45 to 0.95Controlling for region, number of exacerbations in the previous year, use of OCS
SecondaryTime to First Asthma Exacerbation
Time frame:
Immediately following the first administration of study drug through Study Week 56
Reported as:
Number · Participants
Time to First Asthma Exacerbation
ParticipantsBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Time to First Asthma Exacerbation8495126
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Regression, Cox · p = <0.001 · Hazard ratio (hr): 0.61 · 95% CI 0.46 to 0.80Model includes treatment, region, number of exacerbations in the previous year, use of OCS
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Regression, Cox · p = 0.018 · Hazard ratio (hr): 0.73 · 95% CI 0.55 to 0.95Model includes treatment, region, number of exacerbations in the previous year, use of OCS
SecondaryAnnual Rate of Asthma Exacerbation Resulting Emergency Room Visits and Hospitalizations

Annual rate of asthma exacerbations that are associated with an emergency room visit or a hospitalization (adjudicated)

Time frame:
Immediately following the first administration of study drug through Study Week 56.
Reported as:
Least squares mean · Events/year
Annual Rate of Asthma Exacerbation Resulting Emergency Room Visits and Hospitalizations
Events/yearBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Annual Rate of Asthma Exacerbation Resulting Emergency Room Visits and Hospitalizations0.04 (0.02 to 0.06)0.05 (0.03 to 0.08)0.04 (0.02 to 0.07)
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · negative binomial · p = 0.837 · Rate ratio: 0.93 · 95% CI 0.48 to 1.82Model includes treatment, region, any prior exacerbation resulting ER/Hospitalization, use of OCS
  • Benralizumab 30 mg q.8 Weeks vs Placebo · negative binomial · p = 0.538 · Rate ratio: 1.23 · 95% CI 0.64 to 2.35Model includes treatment, region, any prior exacerbation resulting ER/Hospitalization, use of OCS
SecondaryPharmacokinetics of Benralizumab

Mean PK Concentration at each visit

Time frame:
Baseline, Week 4, Week 8, Week 16, Week 24, Week 32, Week 40, Week 48, Week 56, Week 60
Reported as:
Geometric mean · ng/mL
Pharmacokinetics of Benralizumab
ng/mLBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Baseline (n=435, 419)NA ± NANA ± NA—
Week 4 (n=430, 416)650.04 ± 154.61703.16 ± 89.48—
Week 8 (n=414, 395)894.86 ± 148.91939.45 ± 98.99—
Week 16 (n=390, 378)936.43 ± 247.46252.54 ± 274.74—
Week 24 (n=388, 361)827.09 ± 370.64188.99 ± 308.38—
Week 32 (n=345, 323)823.21 ± 362.43166.53 ± 289.34—
Week 40 (n=370, 338)859.69 ± 364.28172.28 ± 298.6—
Week 48 (n=355, 337)888.09 ± 333.98186.5 ± 290.28—
Week 56 (n=358, 344)763.98 ± 309.18173.41 ± 235.86—
Week 60 (n=49, 45)53.63 ± 1782.9618.63 ± 756.47—
SecondaryImmunogenicity of Benralizumab

Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at \>=2 post-baseline assessments (with \>=16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive is defined as having at least one post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.

Time frame:
Pre-treatment until end of follow-up
Reported as:
Number · Participants
Immunogenicity of Benralizumab
ParticipantsBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Positive at any visit (n=438, 427, 440)636413
Base- and Post-baseline Postive (n=431, 414, 430)555
Only post-baseline positive (n=431, 420, 436)55578
Persistently positive (n=431, 420, 436)44427
Transient positive (n=431, 420, 436)16206
Only baseline positive (n=438, 421, 434)320
SecondaryExtent of Exposure

Extent of exposure is defined as the duration of treatment in days

Time frame:
Immediately following the first administration of study drug through Study Week 56
Reported as:
Mean · Days
Extent of Exposure
DaysBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Extent of Exposure344.14 ± 73.129331.64 ± 88.839336.69 ± 82.148
SecondaryMean Change From Baseline to Week 56 in AQLQ(S)+12

AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of \>=0.5 are considered clinically meaningful.

Time frame:
Immediately following the first administration of study drug through Study Week 56
Reported as:
Mean · Scores on a scale
Mean Change From Baseline to Week 56 in AQLQ(S)+12
Scores on a scaleBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Mean Change From Baseline to Week 56 in AQLQ(S)+121.44 ± 1.151.61 ± 1.241.32 ± 1.19
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.119 · Mean difference (final values): 0.16 · 95% CI -0.04 to 0.37Model includes treatment, baseline AQLQ score, region, use of OCS, visit, visit by treatment.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.019 · Mean difference (final values): 0.24 · 95% CI 0.04 to 0.45Model includes treatment, baseline AQLQ score, region, use of OCS, visit, visit by treatment.
SecondaryChange From Baseline to Week 56 in EQ-5D-5L VAS

EQ-5D-5L VAS is to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.

Time frame:
Immediately following the first administration of study drug through Study Week 56
Reported as:
Mean · Scores on a scale
Change From Baseline to Week 56 in EQ-5D-5L VAS
Scores on a scaleBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Change From Baseline to Week 56 in EQ-5D-5L VAS13.8 ± 21.5215.5 ± 20.3612.1 ± 20.13
SecondaryMean Work Productivity Loss Due to Asthma

WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Work productivity loss is derived by sum of percentage of missed work due to asthma and product of percentage of actual working hours times degree of asthma affecting work productivity while working. Percentage of missed work due to asthma is calculated by number of hours missed work due to asthma divided by total number of hours missed work plus number of hours actually worked. This is only applicable to patients who were employed.

Time frame:
Immediately following the first administration of study drug through Study Week 56
Reported as:
Mean · Percent of productivity loss
Mean Work Productivity Loss Due to Asthma
Percent of productivity lossBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Mean Work Productivity Loss Due to Asthma26.56 ± 25.58924.44 ± 24.68927.29 ± 25.802
SecondaryMean Productivity Loss Due to Asthma in Classroom

WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Classroom productivity loss is derived by sum of percentage of missed classes due to asthma and product of percentage of actual hours attending classes times degree of asthma affecting classroom productivity. Percentage of missed classes due to asthma is calculated by number of hours missed classes due to asthma divided by total number of hours missed classes plus number of hours actually attending classes. This is only applicable for patients who took classes.

Time frame:
Immediately following the first administration of study drug through Study Week 56
Reported as:
Mean · percent of productivity loss
Mean Productivity Loss Due to Asthma in Classroom
percent of productivity lossBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Mean Productivity Loss Due to Asthma in Classroom19.92 ± 23.76514 ± 16.73333.5 ± 25.593
SecondaryNumber of Participants That Utilized Health Care Resources
Time frame:
Immediately following the first administration of study drug through Study Week 56
Reported as:
Number · Participants
Number of Participants That Utilized Health Care Resources
ParticipantsBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Hospitalizations111412
Emergency department visits111218
Unscheduled outpatient visits727583
Home visits312
Telephone calls506358
Ambulance transports235
SecondaryPatient and Clinician Assessment of Response to Treatment

CGIC (clinician global impression of change), and PGIC (patient global impression of change) are overall evaluation of response to treatment, conducted separately by investigator and patient using a 7-point rating scale, ranging from 1 (Very much Improved), to 7 (Very much Worse). This endpoint was added after the second protocol amendment, thus not all patients had data to be analyzed.

Time frame:
Immediately following the first administration of study drug through Study Week 56
Reported as:
Number · Participants
Patient and Clinician Assessment of Response to Treatment
ParticipantsBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
CGIC, Improved1099697
CGIC, Much Improved827165
CGIC, Very Much Improved262314
CGIC, Total217190176
PGIC, Improved1099599
PGIC, Much Improved838066
PGIC, Very Much Improved343017
PGIC, Total226205182

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Benralizumab 30 mg q.4 Weeks—46/438 (10.5%)244/438 (55.7%)
Benralizumab 30 mg q.8 Weeks—41/428 (9.6%)232/428 (54.2%)
Placebo—61/440 (13.9%)264/440 (60%)
Most frequent serious events
Showing 10 of 99
Most frequent serious events
EventBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
AsthmaRespiratory, thoracic and mediastinal disorders21/43819/42823/440
PneumoniaInfections and infestations2/4380/4284/440
Pneumonia bacterialInfections and infestations2/4380/4283/440
InfluenzaInfections and infestations0/4382/4280/440
NephrolithiasisRenal and urinary disorders2/4380/4280/440
Myocardial ischaemiaCardiac disorders0/4380/4282/440
Acute coronary syndromeCardiac disorders0/4381/4280/440
Angina pectorisCardiac disorders0/4381/4280/440
Atrial fibrillationCardiac disorders0/4381/4280/440
CataractEye disorders0/4381/4280/440
Most frequent other events
Showing 10 of 16
Most frequent other events
EventBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
NasopharyngitisInfections and infestations90/43882/42892/440
BronchitisInfections and infestations40/43845/42854/440
AsthmaRespiratory, thoracic and mediastinal disorders50/43832/42852/440
Upper respiratory tract infectionInfections and infestations29/43837/42842/440
SinusitisInfections and infestations23/43821/42839/440
HeadacheNervous system disorders33/43834/42832/440
InfluenzaInfections and infestations24/43812/42825/440
Rhinitis allergicRespiratory, thoracic and mediastinal disorders21/43816/42824/440
HypertensionVascular disorders12/43818/42822/440
RhinitisInfections and infestations12/43818/42817/440

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Benralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlaceboTotal
Mean50.0 ± 13.649 ± 14.348.8 ± 15.149.2 ± 14.3
Gender
Gender(Participants)Benralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlaceboTotal
Female270273264807
Male155168176499
08

Study locations

217 sites
  • Research Site
    Andalusia, Alabama, United States
  • Research Site
    Birmingham, Alabama, United States
  • Research Site
    Flagstaff, Arizona, United States
  • Research Site
    Glendale, Arizona, United States
  • Research Site
    Phoenix, Arizona, United States
  • Research Site
    Tucson, Arizona, United States
  • Research Site
    Alhambra, California, United States
  • Research Site
    Anaheim, California, United States
  • Research Site
    Beverly Hills, California, United States
  • Research Site
    Garden Grove, California, United States
  • Research Site
    Lakewood, California, United States
  • Research Site
    North Hollywood, California, United States
  • Research Site
    Northridge, California, United States
  • Research Site
    Palmdale, California, United States
  • Research Site
    Rancho Mirage, California, United States
  • Research Site
    Redondo Beach, California, United States
  • Research Site
    Rolling Hills Estate, California, United States
  • Research Site
    Sacramento, California, United States
  • Research Site
    Stockton, California, United States
  • Research Site
    Thousand Oaks, California, United States
  • Research Site
    Upland, California, United States
  • Research Site
    Ventura, California, United States
  • Research Site
    Walnut Creek, California, United States
  • Research Site
    Westminister, California, United States
  • Research Site
    Woodland, California, United States
  • Research Site
    Centennial, Colorado, United States
  • Research Site
    Colorado Springs, Colorado, United States
  • Research Site
    Wheat Ridge, Colorado, United States
  • Research Site
    Celebration, Florida, United States
  • Research Site
    Fort Lauderdale, Florida, United States
  • Research Site
    Hialeah, Florida, United States
  • Research Site
    Homestead, Florida, United States
  • Research Site
    Jacksonville, Florida, United States
  • Research Site
    Lehigh Acres, Florida, United States
  • Research Site
    Miami, Florida, United States
  • Research Site
    Ocala, Florida, United States
  • Research Site
    Orlando, Florida, United States
  • Research Site
    Ormond Beach, Florida, United States
  • Research Site
    Virginia Gardens, Florida, United States
  • Research Site
    Gainesville, Georgia, United States
  • Research Site
    Smyrna, Georgia, United States
  • Research Site
    Eagle, Idaho, United States
  • Research Site
    Shiloh, Illinois, United States
  • Research Site
    Lenexa, Kansas, United States
  • Research Site
    Fort Mitchell, Kentucky, United States
  • Research Site
    Covington, Louisiana, United States
  • Research Site
    Bangor, Maine, United States
  • Research Site
    Farmington Hills, Michigan, United States
  • Research Site
    Flint, Michigan, United States
  • Research Site
    Traverse City, Michigan, United States
  • Research Site
    Minneapolis, Minnesota, United States
  • Research Site
    St Louis, Missouri, United States
  • Research Site
    Las Vagas, Nevada, United States
  • Research Site
    Union, New Jersey, United States
  • Research Site
    Bronx, New York, United States
  • Research Site
    Durham, North Carolina, United States
  • Research Site
    Wilmington, North Carolina, United States
  • Research Site
    Cincinnati, Ohio, United States
  • Research Site
    Columbus, Ohio, United States
  • Research Site
    Dayton, Ohio, United States
  • Research Site
    Middleburg Heights, Ohio, United States
  • Research Site
    Oklahoma City, Oklahoma, United States
  • Research Site
    Corvallis, Oregon, United States
  • Research Site
    Portland, Oregon, United States
  • Research Site
    Jefferson Hills, Pennsylvania, United States
  • Research Site
    Pittsburgh, Pennsylvania, United States
  • Research Site
    Indian Land, South Carolina, United States
  • Research Site
    Rapid City, South Dakota, United States
  • Research Site
    Knoxville, Tennessee, United States
  • Research Site
    Arlington, Texas, United States
  • Research Site
    Austin, Texas, United States
  • Research Site
    Boerne, Texas, United States
  • Research Site
    Dallas, Texas, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    San Antonio, Texas, United States
  • Research Site
    Midvale, Utah, United States
  • Research Site
    Murray, Utah, United States
  • Research Site
    Fairfax, Virginia, United States
  • Research Site
    Falls Church, Virginia, United States
  • Research Site
    Madison, Wisconsin, United States
  • Research Site
    Milwaukee, Wisconsin, United States
  • Research Site
    Buenos Aires, Argentina
  • Research Site
    Caba, Argentina
  • Research Site
    Ciudad Autónoma de Bs. As., Argentina
  • Research Site
    Ciudad de Buenos Aires, Argentina
  • Research Site
    Concepción del Uruguay, Argentina
  • Research Site
    Corrientes, Argentina
  • Research Site
    Córdoba, Argentina
  • Research Site
    Florida, Argentina
  • Research Site
    Godoy Cruz, Argentina
  • Research Site
    La Plata, Argentina
  • Research Site
    Mar del Plata, Argentina
  • Research Site
    Mendoza, Argentina
  • Research Site
    Ranelagh, Argentina
  • Research Site
    Rosario, Argentina
  • Research Site
    San Miguel de Tucuman, Argentina
  • Research Site
    Calgary, Alberta, Canada
  • Research Site
    Sherwood Park, Alberta, Canada
  • Research Site
    Vancouver, British Columbia, Canada
  • Research Site
    Moncton, New Brunswick, Canada

Showing the first 100 of 217 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, Jison M, Brooks CL, Papeleu P, Katial R. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab. Adv Ther. 2022 May;39(5):2065-2084. doi: 10.1007/s12325-022-02098-1. Epub 2022 Mar 14. PubMed 35287231 ↗
  • Lugogo NL, Kreindler JL, Martin UJ, Cook B, Hirsch I, Trudo FJ. Blood eosinophil count group shifts and kinetics in severe eosinophilic asthma. Ann Allergy Asthma Immunol. 2020 Aug;125(2):171-176. doi: 10.1016/j.anai.2020.04.011. Epub 2020 Apr 22. PubMed 32334141 ↗
  • Jackson DJ, Humbert M, Hirsch I, Newbold P, Garcia Gil E. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma. Adv Ther. 2020 Feb;37(2):718-729. doi: 10.1007/s12325-019-01191-2. Epub 2019 Dec 14. PubMed 31836949 ↗
  • Chipps BE, Hirsch I, Trudo F, Alacqua M, Zangrilli JG. Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma. Ann Allergy Asthma Immunol. 2020 Jan;124(1):79-86. doi: 10.1016/j.anai.2019.10.006. Epub 2019 Oct 15. PubMed 31626906 ↗
  • Chupp G, Lugogo NL, Kline JN, Ferguson GT, Hirsch I, Goldman M, Zangrilli JG, Trudo F. Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2019 May;122(5):478-485. doi: 10.1016/j.anai.2019.02.016. Epub 2019 Feb 23. PubMed 30802500 ↗
  • Bleecker ER, Wechsler ME, FitzGerald JM, Menzies-Gow A, Wu Y, Hirsch I, Goldman M, Newbold P, Zangrilli JG. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018 Oct 18;52(4):1800936. doi: 10.1183/13993003.00936-2018. Print 2018 Oct. PubMed 30139780 ↗
  • DuBuske L, Newbold P, Wu Y, Trudo F. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab. Allergy Asthma Proc. 2018 Sep 4;39(5):345-349. doi: 10.2500/aap.2018.39.4162. Epub 2018 Aug 4. PubMed 30077185 ↗
  • Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2018 May;120(5):504-511.e4. doi: 10.1016/j.anai.2018.01.030. Epub 2018 Feb 1. PubMed 29409951 ↗
  • Ohta K, Adachi M, Tohda Y, Kamei T, Kato M, Mark Fitzgerald J, Takanuma M, Kakuno T, Imai N, Wu Y, Aurivillius M, Goldman M. Efficacy and safety of benralizumab in Japanese patients with severe, uncontrolled eosinophilic asthma. Allergol Int. 2018 Apr;67(2):266-272. doi: 10.1016/j.alit.2017.10.004. Epub 2017 Nov 8. PubMed 29128192 ↗
  • FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, Gilmartin G, Werkstrom V, Aurivillius M, Goldman M; CALIMA study investigators. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29;388(10056):2128-2141. doi: 10.1016/S0140-6736(16)31322-8. Epub 2016 Sep 5. PubMed 27609406 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Mar 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2013
First posted
Aug 2, 2013
Start
Aug 2013
Primary completionActual
Mar 2016
CompletionActual
Mar 2016
Results first posted
Jan 25, 2017
Last update
Jan 25, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01914757
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 2, 2013
Start date
Aug 2013
Primary completion
Mar 2016
Completion
Mar 2016
Results posted
Jan 25, 2017
Last update
Jan 25, 2017

Study contacts

Mark Fitzgerald, MD, PhD, Professor of Medicine
principal investigator · The Lung Centre, Gordon and Leslie Diamond Health Care Centre, Vancouver Canada

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion